NeoPharm Inc. (NEOL) Stock Quote

Stock Web

Detailed Quote for NeoPharm Inc. (NEOL)

close 52 Week Information

52 Week High

October 13,2009

Close: 0.55

52 Week Low

September 21,2009

Close: 0.19

Today

5d

1m

3m

1y

more

Last Price
0.251

Change $
0.009

Change %
3.46%

Tick

Bid
N/A

Bid Size
N/A

Ask
N/A

Ask Size
N/A

Open
0.251

High
0.251

Low
0.251

Prev Close
0.26

Last Trade
9:49

Volume
2 k

52 Wk Hi
0.55

52 Wk Low
0.19

Market Cap
7.15 m

Ex-Div Date
N/A

Div Rate
N/A

Yield
N/A

Shares
28,497,049

EPS (TTM)
N/A

PE Ratio
N/A

close Exchange Information Listed On Other-OTC (Pinks) Exchange
Pinks

News and Media for NeoPharm Inc. (NEOL)

Sector News | Topic News

News for NEOL

Thu, Aug 26, 2010

8:00 AM

NeoPharm, Inc. Announces Second Quarter 2010 Financial Results - Business Wire

Fri, Jun 11, 2010

8:02 AM

NeoPharm, Inc. Announces First Quarter 2010 Financial Results and Clinical Trial Update - Business Wire

Tue, Sep 01, 2009

6:51 AM

InvestorSoup.com Issues Technical Trading Outlook for BioNeutral Group Inc. - Globe Newswire

Fri, Jul 14, 2006

12:00 PM

NeoPharm, Inc. (NEOL) President and CEO to Ring the NASDAQ Stock Market Closing Bell - Globe Newswire

Thu, Aug 25, 2005

10:01 AM

Cell Therapeutics, Inc. Plans to Submit Marketing Applications for Potential Approval of XYOTAX and NeoPharm Gets FDA Approval to Conduct Data Analysis during Brain Tumor Treatment Trial - Financial News USA

More News for NEOL >>

Tags for NeoPharm Inc.

Research stocks or mutual funds related to NeoPharm Inc. by keywords or tags. Find companies that have a similar focus to NEOL. The keywords below have been associated to NEOL by either user submission or electronic means.

advanced therapy clinical trials database nasal drug delivery types of brain tumor pharmaceutical market pivotal therapy system new drug delivery systems hr strategy Biological Products pharma manufacturing pharma license phase iii clinical trials Brain tumor drug delivery pharmaceutical cro pharma consulting malignant astrocytoma drug absorption clinical trials industry pharmaceutical distributors pharma in licensing licensing companies pharmaceutical development topical drug delivery pharmaceutical magazine pharmaceutical consultant biotechnology licensing worldwide clinical trials Drugs pharma clinical trials pharmaceutical industry news pharmaceutical manufacturing software pharmaceutical manufacturing pharmaceutical formulation hairy cell leukemia therapy contract pharmaceutical pharmaceutical industry clinical trials europe cancer veterinary pharmaceutical pharmaceutical advances pharmaceutical distributor pharmaceutical out licensing pharmaceutical business development Healthcare pharmaceutical sector neopharm drug delivery systems pharmaceutical industry research controlled drug delivery

Bookmark With:

Financial Market Data powered by QuoteMedia.com. All rights reserved. View the Terms of Use
NYSE/AMEX data delayed 20 minutes. NASDAQ and other data delayed 15 minutes unless indicated.
RT Realtime, EOD End Of Day, PD Previous Day. PW Previous Week.

All information displayed and available herein is on an "as is", "as available" basis and neither InvestorPoint.com nor any of its underlying service providers, information providers, licensors, employees, distributors or agents make any representations as to the suitability of our service or the materials for any purpose. The information is not intended for trading purposes or advice. We specifically disclaim any representations or warranties, express or implied, including, without limitation, any representations or warranties of merchantability or fitness for a particular purpose. InvestorPoint.com is not an investment adviser. We do not: (a) give investment advice, (b) advocate the purchase or sale of any security or investment and (c) provide, endorse or review any information or data contained herein. We do not guarantee the accuracy of the information and data supplied by information providers. We are not liable or responsible for the quality, accuracy or reliability of this information. You should always seek the assistance of a professional for investment advice.